Pharma channel feed

CHMP rec­om­mends five new drugs, re­con­sid­ers Eli Lil­ly’s Kisun­la 

3 weeks ago
FDA+

Phar­ma com­pa­nies are weigh­ing how a drug’s IP lo­ca­tion could im­pact tar­iffs

3 weeks ago
Manufacturing

UK's NICE says Lil­ly, Ei­sai's Alzheimer's drugs aren't worth na­tion­al cov­er­age

3 weeks ago

Grail shares jump on study re­sults for can­cer test

3 weeks ago
Diagnostics

Gilead gets ground­break­ing FDA ap­proval for twice-year­ly HIV pre­ven­tion shot 

3 weeks ago
FDA+

Com­pounders lose case over semaglu­tide short­age

3 weeks ago
Health Tech

CBER head Prasad adds chief med­ical and sci­en­tif­ic of­fi­cer to his ti­tle

3 weeks ago
FDA+

Q&A: New BIO chair to steer in­dus­try through ‘ex­is­ten­tial threats’ de­spite FDA re­cep­tiv­i­ty

3 weeks ago
R&D
China

Or­phan drug, PBM changes are ex­clud­ed from Sen­ate ver­sion of Trump tax bill

4 weeks ago
Law

FDA ap­proves CSL’s pro­phy­lac­tic for se­vere swelling con­di­tion

4 weeks ago
FDA+

Fired vac­cine ad­vi­sors de­fend ACIP’s work, in­de­pen­dence in joint ed­i­to­r­i­al

4 weeks ago
R&D

Pur­due opi­oid set­tle­ment gets back­ing from 55 at­tor­neys gen­er­al

4 weeks ago
Law

Eli Lil­ly makes all Zep­bound dos­es avail­able in sin­gle-dose vials 

4 weeks ago
Marketing

Ab­b­Vie’s can­cer drug fails Phase 3 com­bo study to treat oth­er bone mar­row dis­eases

4 weeks ago
R&D

KalVista says FDA de­layed de­ci­sion on HAE drug, cit­ing ‘heavy work­load’ 

4 weeks ago
FDA+

FDA's on­col­o­gy ad­comm to re­view GSK's Blenrep re­launch plans

4 weeks ago
FDA+

With HIV pre­ven­tion un­der at­tack, how might Gilead’s new PrEP in­jec­tion fare?

4 weeks ago
In Focus

Mod­er­na wins ex­pand­ed la­bel for RSV shot, al­low­ing use in at-risk, younger adults

4 weeks ago
FDA+

Min­neso­ta gener­ic drug pric­ing law is like­ly un­con­sti­tu­tion­al, ap­peals court rules

4 weeks ago
Law

No­vo Nordisk plans Phase 3 tri­als of oral, in­jectable amy­cretin for ear­ly 2026

4 weeks ago
R&D

Kennedy's vac­cine doubts hinge on 'in­ert' place­bos, but ex­perts say he mis­un­der­stands the sci­ence

4 weeks ago
FDA+

In sur­prise, FDA ap­proves Uro­Gen's chemo-turned-gel drug af­ter neg­a­tive ad­comm vote

4 weeks ago
FDA+

Ex­clu­sive: Kennedy picks for vac­cine ad­vi­so­ry board were paid ex­perts against Mer­ck in civ­il cas­es

4 weeks ago
R&D
FDA+

RFK Jr. names eight new ACIP mem­bers, in­clud­ing pop­u­lar vac­cine crit­ic Robert Mal­one

4 weeks ago
FDA+
First page Previous page 123456 Next page Last page
A service from the Financial Times